Literature DB >> 28561

beta-lactamases in bacteroides.

C E Nord, B Olsson, K Dornbusch.   

Abstract

Bacteroides fragilis is responsible for most anaerobic infections in man. Most isolates of B. fragilis show resistance to beta-lactam antibiotics. This resistance might be due to beta-lactamase production or permeability barrier in the cell wall. B. fragilis produce beta-lactamase with mainly cephalosporinase activity. Other Bacteroides species such as B. clostridiformis, B. melaninogenicus and B. oralis also produce beta-lactamase but with different biochemical characteristics.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 28561

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  6 in total

1.  Emergence of beta-lactamase producing anaerobic bacteria in the tonsils during penicillin treatment.

Authors:  K Tunér; C E Nord
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

2.  Impact on peritonsillar infections and microflora of phenoxymethylpenicillin alone versus phenoxymethylpenicillin in combination with metronidazole.

Authors:  K Tunér; C E Nord
Journal:  Infection       Date:  1986 May-Jun       Impact factor: 3.553

3.  Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production.

Authors:  M A Crosby; D W Gump
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

4.  Studies on beta-lactamase in Bacteroides fragilis.

Authors:  C E Nord; K Dornbusch; B Olsson
Journal:  Infection       Date:  1980       Impact factor: 3.553

5.  Factors contributing to resistance to beta-lactam antibiotics in Bacteroides fragilis.

Authors:  B Olsson; K Dornbusch; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

Review 6.  Cefuroxime: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-04       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.